Literature DB >> 28188189

Vascular Invasion and Metastasis is Predictive of Outcome in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma.

Ali A Mokdad1, Amit G Singal2, Jorge A Marrero2, Hao Zhu3, Adam C Yopp1.   

Abstract

Background: Patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) have variable long-term outcomes. Better delineation of prognosis is important for clinical trial enrollment and clinical practice in an era of precision medicine. We hypothesized that stratification of patients with BCLC stage C HCC by presence of vascular invasion and/or metastasis improves prognostic discrimination.
Methods: Using a prospectively maintained database, we identified 234 patients diagnosed with BCLC stage C HCC between 2005 and 2015. Patients were stratified into 3 groups based on tumor characteristics: (1) vascular invasion alone, (2) metastasis alone, and (3) vascular invasion and metastasis. Overall survival (OS) was compared using a Cox model. A subgroup analysis was performed based on extent of vascular invasion and site of metastasis.
Results: The cohort comprised 123 patients (53%) with vascular invasion alone, 34 (15%) with metastasis alone, and 77 (33%) with both vascular invasion and metastasis. Median survival was 5.7, 3.9, and 3.0 months, respectively (P<.01). Patients with vascular invasion or metastasis alone had significantly better survival compared with those with vascular invasion and metastasis (adjusted hazard ratio [HR],0.68; 95% CI, 0.49-0.94, and HR, 0.61; 95% CI, 0.39-0.96, respectively). Compared with tumoral invasion of branch portal veins, involvement of the main portal vein was associated with worse survival (HR, 2.13; 95% CI, 1.29-3.49). OS did not differ by site of metastasis. Conclusions: Stratification of patients within the BCLC stage C staging subgroup by vascular invasion and presence of metastasis further discriminates patient prognosis. This substratification may have implications for therapy and more accurate prognostic features.
Copyright © 2017 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2017        PMID: 28188189     DOI: 10.6004/jnccn.2017.0020

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  12 in total

1.  Prognostic Significance of Preoperative Gamma-Glutamyltransferase to Alkaline Phosphatase Ratio in Hepatocellular Carcinoma Patients with Curative Liver Resection: A Retrospective Cohort Study.

Authors:  Guoqing Ouyang; Guangdong Pan; Yongrong Wu; Qiang Liu; Wuchang Lu; Xiang Chen
Journal:  Cancer Manag Res       Date:  2020-09-21       Impact factor: 3.989

2.  Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).

Authors:  Ying Ding; Sheng-Xiang Rao; Wen-Tao Wang; Cai-Zhong Chen; Ren-Chen Li; Mengsu Zeng
Journal:  Cancer Imaging       Date:  2018-12-07       Impact factor: 3.909

3.  The power of tumor sizes in predicting the survival of solitary hepatocellular carcinoma patients.

Authors:  Anli Yang; Weikai Xiao; Dong Chen; Xiaoli Wei; Shanzhou Huang; Ye Lin; Chuanzhao Zhang; Jianwei Lin; Feiwen Deng; Chenglin Wu; Xiaoshun He
Journal:  Cancer Med       Date:  2018-11-14       Impact factor: 4.452

Review 4.  Efficacy and safety of various primary treatment strategies for very early and early hepatocellular carcinoma: a network meta-analysis.

Authors:  Sha Yang; Huapeng Lin; Jianning Song
Journal:  Cancer Cell Int       Date:  2021-12-19       Impact factor: 5.722

Review 5.  Exosomal Non-Coding RNAs: New Insights into the Biology of Hepatocellular Carcinoma.

Authors:  Qian Zhang; Hanlin Li; Yang Liu; Jian Li; Chunling Wu; Hua Tang
Journal:  Curr Oncol       Date:  2022-07-29       Impact factor: 3.109

6.  Characterization of somatic mutations and pathway alterations during hepatocellular carcinoma vascular invasion using next-generation sequencing.

Authors:  Qi Li; Qifan Zhang; Jinzhang Chen; Mengya Zang; Xiaoyun Hu; Rong Li; Jinlin Hou; Jie Zhou
Journal:  J Gastrointest Oncol       Date:  2022-08

7.  A new mild hyperthermia device to treat vascular involvement in cancer surgery.

Authors:  Matthew J Ware; Lam P Nguyen; Justin J Law; Martyna Krzykawska-Serda; Kimberly M Taylor; Hop S Tran Cao; Andrew O Anderson; Merlyn Pulikkathara; Jared M Newton; Jason C Ho; Rosa Hwang; Kimal Rajapakshe; Cristian Coarfa; Shixia Huang; Dean Edwards; Steven A Curley; Stuart J Corr
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

8.  Macroscopic Portal Vein Thrombosis in HCC Patients.

Authors:  Hikmet Akkiz; Brian I Carr; Sedef Kuran; Ümit Karaoğullarından; Oguz Üsküdar; Salih Tokmak; Burcu Arslan; Figen Doran; Hüseyin Tugsan Balli; Abdulalh Ülkü; Tolga Atılgan Akçam; Halil İbrahim Bahçeci; Kamil Yalçın Polat; Necati Örmeci; Halis Şimşek; Abdullah Sonsuz; Ali Demir; Engin Altıntaş; Mehmet Demir; Kendal Yalçın; Nazım Ekinci; Ayşegül Harmancı Özakyol; Mehmet Yücesoy; Ahmet Uygun; Vito Guerra; Anıl Delik; Yaman Tokat; Sezai Yilmaz; Ahmet Bektaş; Murat Kılıç
Journal:  Can J Gastroenterol Hepatol       Date:  2018-06-13

9.  Increased expression of long non-coding RNA CCAT2 predicts poorer prognosis in patients with hepatocellular carcinoma.

Authors:  Changbo Fu; Xuan Xu; Weijun Lu; Lei Nie; Tao Yin; Dongde Wu
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

Review 10.  Challenging the Treatment Paradigm: Selecting Patients for Surgical Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Authors:  Nicole M Nevarez; Adam C Yopp
Journal:  J Hepatocell Carcinoma       Date:  2021-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.